Hepatitis B Chronic clinical trials

Explore recruiting hepatitis b chronic clinical trials.

Recruiting hepatitis b chronic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatitis B Chronic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

Bulgaria, France, Italy, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.

Belgium, Italy, Germany, Romania, France, Spain +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tide analogue (NA) therapy.

Belgium, Germany, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 2)

Romania, Germany, Poland, France, Hungary, Italy +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1)

Spain, Romania, France, Hungary, Italy, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hepatitis B Chronic trials by city

Hepatitis B Chronic in Toronto Hepatitis B Chronic in Vancouver Hepatitis B Chronic in Montreal Hepatitis B Chronic in Calgary Hepatitis B Chronic in Edmonton Hepatitis B Chronic in Ottawa Hepatitis B Chronic in Winnipeg Hepatitis B Chronic in Quebec City Hepatitis B Chronic in Hamilton Hepatitis B Chronic in Kitchener Hepatitis B Chronic in London Hepatitis B Chronic in Halifax Hepatitis B Chronic in New York Hepatitis B Chronic in Los Angeles Hepatitis B Chronic in Chicago Hepatitis B Chronic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease